ZGNX - Zogenix sees 4Q Fintepla sales of ~$8M

Zogenix ([[ZGNX]] -3.5%) reports preliminary 4Q Fintepla sales of about $8.1M, drug treats seizures associated with Dravet syndrome, topping the average revenue estimate of $6.2M.While it’s “still early days” in a drug launch with “a good deal of investor skepticism,” a sequential quarterly increase of ~250 additional patients on reimbursed therapy “puts ZGNX on a nice track to meet or beat 2021 Fintepla consensus,” Stifel analyst Paul Matteis (buy) wrote in a note. He still expects the pandemic to “inevitably slow the process of (and delay some patients’ willingness for) obtaining pre-treatment echocardiograms”ZGNX cash/equivalents $505.8M.As of December 31, 2020, more than 550 patients had been prescribed Fintepla and were enrolled in the REMS program, and 416 patients were receiving reimbursed therapy.Fintepla announced FDA and European approval during last year.

For further details see:

Zogenix sees 4Q Fintepla sales of ~$8M